Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer

IMPORTANCE: Immune checkpoint inhibitors (ICIs) can elicit durable antitumor responses in patients with non–small cell lung cancer (NSCLC), but only 20% to 25% of patients respond to treatment. As important genes in the DNA damage response pathway, comutation in the tumor protein p53 (TP53) and atax...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Netw Open
Autors principals: Chen, Yu, Chen, Gang, Li, Jin, Huang, Ying-Ying, Li, Yi, Lin, Jing, Chen, Li-Zhu, Lu, Jian-Ping, Wang, Yu-Qi, Wang, Chang-Xi, Pan, Leong Kin, Xia, Xue-Feng, Yi, Xin, Chen, Chuan-Ben, Zheng, Xiong-Wei, Guo, Zeng-Qing, Pan, Jian-Ji
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2019
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6755545/
https://ncbi.nlm.nih.gov/pubmed/31539077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.11895
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars